Micafungin Pharmazac (Micafungin)

Micafungin is used to treat and prevent invasive Candida infections across several clinical settings.

• Invasive candidiasis: eradicates bloodstream and deep‑tissue Candida infections in immunocompromised patients.
• Esophageal candidiasis: resolves mucosal infection and associated pain in patients with esophageal involvement.
• Candida peritonitis and intra‑abdominal infections: clears fungal contamination following abdominal surgery or perforation.
• Prophylaxis in hematopoietic stem‑cell transplantation: prevents Candida infection during the neutropenic phase of transplant conditioning.

• Micafungin inhibits the fungal enzyme β‑(1,3)‑D‑glucan synthase, which is essential for synthesis of β‑(1,3)‑D‑glucan, a critical component of the fungal cell wall. By blocking this pathway, micafungin weakens cell wall integrity, leading to osmotic instability and cell lysis, while having minimal effect on human cells that lack this enzyme. The drug is administered intravenously, achieving high plasma concentrations that penetrate tissues and biofilms, and is metabolized primarily by hepatic enzymes without significant renal excretion.

Micafungin may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Fever: transient elevation of body temperature during or after infusion.
• Nausea: mild to moderate sensation of stomach upset.
• Vomiting: occasional episodes following administration.
• Headache: mild headache reported during treatment.
• Elevated liver enzymes: temporary increase in ALT or AST levels.
• Infusion‑related reactions: flushing, erythema, or mild hypotension.

Serious or Rare Side Effects

• Severe hepatic dysfunction: marked elevation of liver enzymes or jaundice.
• Anaphylaxis: acute hypersensitivity reaction with respiratory distress.
• Acute renal failure: sudden decline in kidney function.
• Severe hypotension: marked drop in blood pressure requiring intervention.
• Stevens‑Johnson syndrome: rare severe skin reaction.
• Cardiac arrhythmias: irregular heart rhythms observed in some patients.

Before initiating micafungin therapy, clinicians should consider several safety precautions to minimize risk.

• Monitor liver function: assess baseline ALT/AST and repeat during treatment.
• Assess renal function: evaluate serum creatinine, especially in patients with pre‑existing kidney disease.
• Evaluate for hypersensitivity: discontinue if signs of allergic reaction appear.
• Use caution in cardiac disease: monitor blood pressure and heart rate during infusion.
• Adjust in severe hepatic impairment: consider dose modification or alternative therapy.
• Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with other medicines, affecting its concentration or the effect of concomitant drugs.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin): may markedly reduce micafungin levels.
• Co‑administration with other echinocandins: increased risk of additive toxicity.
• Concurrent use with potent P‑glycoprotein inhibitors: potential for elevated exposure.

Moderate Interactions (Monitor Closely)

• Azole antifungals (e.g., fluconazole, voriconazole): may increase micafungin plasma concentrations.
• Immunosuppressants (cyclosporine, tacrolimus): may require dose adjustment and therapeutic drug monitoring.
• Warfarin: possible increase in INR, monitor coagulation parameters.
• Statins (e.g., simvastatin): monitor for signs of myopathy.
• Oral contraceptives: assess efficacy, consider alternative contraception.